StockNews.AI
NVNO
StockNews.AI
110 days

enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24

1. Q1 cash burn of $4 million aligns with projections for NVNO. 2. FDA decision for VenoValve expected in H2 2025, supporting future growth.

3m saved
Insight
Article

FAQ

Why Bullish?

The anticipated FDA decision and ongoing funding put NVNO in a favorable position. Historical examples show stocks often rise in anticipation of FDA approvals.

How important is it?

The outlined cash position and upcoming FDA decisions are crucial for assessing NVNO's financial health and growth potential.

Why Long Term?

The FDA decision and subsequent market entry will influence NVNO’s growth over the next couple of years.

Related Companies

ABMDMDTBSX
Cash Burn of $4.0 million in Q1 remains in line with projected quarterly range Cash and investments on hand are sufficient to fund operations beyond the anticipated FDA decision of VenoValve and the initiation of the enVVe pivotal trial FDA decision on PMA application for the VenoValve expected in the second half of 2025 On track for enVVe IDE application submission in Q3 of 2025, pending GLP study results IRVINE, CA / ACCESS Newswire / May 1, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today reported financial results for the first quarter 2025. Robert Berman, enVVeno Medical's Chief Executive Officer, commented "In the first quarter, we continued to present our compelling 1-year data from the U.S. pivotal trial at leading global, scientific conferences to socialize and engage directly with leading vascular surgeons as we lay the foundation for the potential phased market entry of the VenoValve, pending FDA approval.

Related News